Cover Image

The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer

The prognosis of patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC) is poor. There is no standard treatment available. Emerging evidence suggests a major role for antiangiogenic treatment modalities in EOC, in particular in combination with the metronomic application of low...

Full description

Saved in:
Bibliographic Details
Main Authors: Eichbaum, Michael H. R. (Author) , Mayer, Christine (Author) , Eickhoff, Regina (Author) , Bischofs, Esther (Author) , Gebauer, Gerhard (Author) , Fehm, Tanja (Author) , Lenz, Florian (Author) , Fricke, Hans-Christian (Author) , Solomayer, Erich (Author) , Fersis, Nikos (Author) , Schmidt, Marcus (Author) , Wallwiener, Markus (Author) , Schneeweiss, Andreas (Author) , Sohn, Christof (Author)
Format: Article (Journal)
Language:English
Published: 20 October 2011
In: BMC cancer
Year: 2011, Volume: 11, Pages: 1-9
ISSN:1471-2407
DOI:10.1186/1471-2407-11-453
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-11-453
Get full text
Author Notes:Michael Eichbaum, Christine Mayer, Regina Eickhoff, Esther Bischofs, Gerhard Gebauer, Tanja Fehm, Florian Lenz, Hans-Christian Fricke, Erich Solomayer, Nikos Fersis, Marcus Schmidt, Markus Wallwiener, Andreas Schneeweiss and Christof Sohn
Description
Summary:The prognosis of patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC) is poor. There is no standard treatment available. Emerging evidence suggests a major role for antiangiogenic treatment modalities in EOC, in particular in combination with the metronomic application of low dose chemotherapy. The novel, investigational oral antiangiogenic agent pazopanib targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit is currently being studied in different tumour types and is already used as first line therapy in recurrent renal cell carcinoma. A combined therapy consisting of pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, pretreated EOC.
Item Description:Gesehen am 08.04.2022
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-11-453

Similar Items